Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

Christopher Brightling discusses the effect of blocking thymic
stromal lymphopoietin (TSLP) with tezepelumab in patients with
moderate-to-severe uncontrolled asthma.

Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext


Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv